The McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine; Baltimore, MD, USA.
Cancer Biol Ther. 2009 Nov;8(21):2013-24. doi: 10.4161/cbt.8.21.9685.
MicroRNAs (miRNAs) are 21-24 nucleotide RNA molecules that regulate the translation and stability of target messenger RNAs. Abnormal miRNA expression is a common feature of diverse cancers. Several previous studies have classified miRNA expression in pancreatic ductal adenocarcinoma (PDAC), although no uniform pattern of miRNA dysregulation has emerged. To clarify these previous findings as well as to set the stage for detailed functional analyses, we performed global miRNA expression profiling of 21 human PDAC cell lines, the most extensive panel studied to date. Overall, 39 miRNAs were found to be dysregulated and have at least two-fold or greater differential expression in PDAC cell lines compared to control nontransformed pancreatic ductal cell lines. Several of these miRNAs show comparable dysregulation in first-passage patient derived xenografts. Initial functional analyses demonstrate that enforced expression of miRNAs derived from the miR-200 family and the miR-17-92 cluster, both of which are overexpressed in PDAC cell lines, enhances proliferation. In contrast, inhibition of the miR-200 family, the miR-17-92 cluster, or miR-191 diminishes anchorage independent growth. Consistent with a known role for the miR-200 family in negatively regulating an epithelial-to-mesenchymal transition (EMT), the abundance of these miRNAs correlated positively with E-cadherin expression and negatively with the EMT-associated transcription factor and established miR-200 target ZEB1. Finally, restituted expression of miR-34a, a miRNA whose expression is frequently lost in PDAC cell lines, abrogates growth, demonstrating that the anti-proliferative activity of this miRNA is operative in PDAC. These results, and the widespread availability of PDAC cell lines wherein the aforementioned data were generated, provide a valuable resource for the pancreatic cancer research community and will greatly facilitate functional studies essential for elucidating the consequences of miRNA dysregulation in pancreatic cancer.
微小 RNA(miRNAs)是 21-24 个核苷酸的 RNA 分子,可调节靶信使 RNA 的翻译和稳定性。异常的 miRNA 表达是多种癌症的共同特征。虽然以前的几项研究已经对胰腺导管腺癌(PDAC)中的 miRNA 表达进行了分类,但 miRNA 失调的模式尚未出现一致。为了阐明这些先前的发现,并为详细的功能分析奠定基础,我们对 21 个人类 PDAC 细胞系进行了全局 miRNA 表达谱分析,这是迄今为止研究最多的细胞系。总体而言,与对照非转化胰腺导管细胞系相比,在 PDAC 细胞系中发现 39 个 miRNA 失调,并且至少有两倍或更大的差异表达。这些 miRNA 中的一些在首次通过患者来源的异种移植中显示出类似的失调。初步功能分析表明,miR-200 家族和 miR-17-92 簇衍生的 miRNA 的强制表达均在 PDAC 细胞系中过度表达,可增强增殖。相反,抑制 miR-200 家族、miR-17-92 簇或 miR-191 会减少无锚定的生长。与 miR-200 家族在负调控上皮-间充质转化(EMT)中已知的作用一致,这些 miRNA 的丰度与 E-钙粘蛋白的表达呈正相关,与 EMT 相关的转录因子和已建立的 miR-200 靶标 ZEB1 呈负相关。最后,miR-34a 的表达恢复,miR-34a 是 PDAC 细胞系中经常丢失的 miRNA,可消除生长,表明该 miRNA 的抗增殖活性在 PDAC 中起作用。这些结果以及广泛提供上述数据的 PDAC 细胞系为胰腺癌研究界提供了宝贵的资源,并将极大地促进阐明 miRNA 失调对胰腺癌的影响所必需的功能研究。